What is Organon?
Organon is a women's health and established medicines company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Women's health and established medicines
- Headquarters
- Jersey City, NJ
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; NYSE: OGN
What is Organon?
Organon is a women's health and established medicines company headquartered in Jersey City, NJ. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Organon is a women's health and established medicines company headquartered in Jersey City, NJ. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Organon should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Organon offer?
Organon's profile centers on Women's health, Biosimilars, Established brands, Fertility products.
- Women's health· Women's health and established medicines
- Biosimilars· Women's health and established medicines
- Established brands· Women's health and established medicines
- Fertility products· Women's health and established medicines
- Contraception· Women's health and established medicines
- International medicines· Women's health and established medicines
How does Organon make money?
Organon makes money through commercial activity tied to women's health and established medicines.
Organon monetizes through the model common to women's health and established medicines: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Organon?
Organon's named executives should be verified on the official leadership or investor-relations page before outreach.
- Organon executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Organon finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Organon operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Organon's leadership?
Organon should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.organon.comHow is Organon funded?
Organon's current status is Public company; NYSE: OGN.
Organon's capital profile is best understood through its current public-company status: Public company; NYSE: OGN. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Organon get here?
Organon's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingOrganon is foundedThe company begins building in women's health and established medicines.
- Scale-upCommercial footprint expandsOrganon broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; NYSE: OGNPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Organon's competitors?
Organon competes with larger incumbents and focused specialists in women's health and established medicines.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Organon — frequently asked questions
